T
Thomas W. Dubensky
Researcher at Chiron Corporation
Publications - 137
Citations - 10499
Thomas W. Dubensky is an academic researcher from Chiron Corporation. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 50, co-authored 132 publications receiving 9316 citations. Previous affiliations of Thomas W. Dubensky include Novartis.
Papers
More filters
Journal ArticleDOI
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales,Laura Hix Glickman,Sarah M. McWhirter,David B. Kanne,Kelsey E. Sivick,George E. Katibah,Seng-Ryong Woo,Edward E. Lemmens,Tamara Banda,Justin Leong,Ken Metchette,Thomas W. Dubensky,Thomas F. Gajewski +12 more
TL;DR: It injection of STING agonists induced profound regression of established tumors in mice and generated substantial systemic immune responses capable of rejecting distant metastases and providing long-lived immunologic memory.
Journal ArticleDOI
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Juan Fu,David B. Kanne,Meredith L. Leong,Laura Hix Glickman,Sarah M. McWhirter,Edward E. Lemmens,Ken Mechette,Justin Leong,Peter Lauer,Weiqun Liu,Kelsey E. Sivick,Qi Zeng,Kevin C. Soares,Lei Zheng,Daniel A. Portnoy,Joshua J. Woodward,Drew M. Pardoll,Thomas W. Dubensky,Young J. Kim +18 more
TL;DR: The authors modified the cyclic dinucleotides to strengthen their binding to human STING, increasing their antitumor activity and showed that treatment with STINGVAX caused cancer cells to up-regulate PD-L1, a protein that suppresses the immune response.
Journal ArticleDOI
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le,Andrea Wang-Gillam,Vincent J. Picozzi,Tim F. Greten,Todd S. Crocenzi,Gregory M. Springett,Michael A. Morse,Herbert J. Zeh,Deirdre Jill Cohen,Robert L. Fine,Beth Onners,Jennifer N. Uram,Daniel A. Laheru,Eric R. Lutz,Sara Solt,Aimee Murphy,Justin Skoble,Ed Lemmens,John Grous,Thomas W. Dubensky,Dirk G. Brockstedt,Elizabeth M. Jaffee +21 more
TL;DR: Heterologous prime/boost vaccination with Cy/GVAX and CRS-207 extended survival for patients with pancreatic cancer, with minimal toxicity.
Journal ArticleDOI
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.
Camie W. Chan,Emily Crafton,Hong Ni Fan,James Flook,Kiyoshi Yoshimura,Mario Skarica,Dirk G. Brockstedt,Thomas W. Dubensky,Monique F. Stins,Lewis L. Lanier,Drew M. Pardoll,Franck Housseau +11 more
TL;DR: In vivo, splenic IKDCs preferentially show NK function and, upon systemic infection, migrate to lymph nodes, where they primarily show antigen-presenting cell activity, which formally distinguish them from classical NK cells.
Journal ArticleDOI
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
Dirk G. Brockstedt,Martin A. Giedlin,Meredith L. Leong,Keith S. Bahjat,Yi Gao,William S. Luckett,Weiqun Liu,David N. Cook,Daniel A. Portnoy,Thomas W. Dubensky +9 more
TL;DR: It is proposed that recombinant Listeria DeltaactA/DeltainlB expressing human tumor-associated antigens represents an attractive therapeutic strategy for further development and testing in human clinical trials.